Esperion Therapeutics Inc ESPR:NASDAQ

Last Price$42.55NASDAQ Closing Price as of 4:00PM ET 7/23/19

Today's Change-0.79(1.82%)
Bid (Size)$42.00 (1)
Ask (Size)$44.00 (10)
Day Low / High$42.16 - 43.51
Volume346.6 K

View Biotechnology IndustryPeer Comparison as of 07/23/2019


Esperion Therapeutics Inc ( NASDAQ )

Price: $42.55
Change: -0.79 (1.82%)
Volume: 346.6 K
4:00PM ET 7/23/2019

Rubius Therapeutics Inc ( NASDAQ )

Price: $13.78
Change: -0.87 (5.94%)
Volume: 113.2 K
4:00PM ET 7/23/2019

Aimmune Therapeutics Inc ( NASDAQ )

Price: $18.77
Change: +0.22 (1.19%)
Volume: 240.1 K
4:00PM ET 7/23/2019

Coherus BioSciences Inc ( NASDAQ )

Price: $18.10
Change: +1.04 (6.10%)
Volume: 1.7 M
4:00PM ET 7/23/2019

Epizyme Inc ( NASDAQ )

Price: $12.83
Change: -0.28 (2.14%)
Volume: 660.1 K
4:00PM ET 7/23/2019

Read more news Recent News

Insider Trends: Insider Buying Prolonged with Purchase of Esperion Therapeutics Shares
4:59PM ET 7/01/2019 MT Newswires

On Jun 28, 2019, Director and President & CEO, Timothy M Mayleben, purchased 5,000 shares in Esperion Therapeutics (ESPR) for $230,000. Subsequent to the...

MT Newswires After-Hours News Movers
5:45PM ET 6/26/2019 MT Newswires

Some of the stocks moving on news-driven events in Wednesday's after-hours include: PECK, +40.46% MLHR, +13.27%% VRCA, +5.49% KBH, +5.18% FNHC, +4.76%...

Esperion Therapeutics Inks Funding Pact with Oberland Capital - Due off After-Hours Halt at 4:40 pm ET
4:22PM ET 6/26/2019 MT Newswires

Esperion Therapeutics (ESPR) and an investor group led by Oberland Capital Management LLC Wednesday night disclosed a $200 million capped, tiered,...

--Esperion Therapeutics Halted After-Hours - News Pending
4:09PM ET 6/26/2019 MT Newswires

Price: 48.63, Change: 0.00, Percent Change: 0.00 ...

View all Commentary and Analysis

Esperion Is The One To Watch, After FDA Deems Advisory Panel Is Not Needed
10:00AM ET 5/22/2019 Seeking Alpha

Bulletproof Investing Performance Update: Week 76
10:33AM ET 5/09/2019 Seeking Alpha

Esperion Therapeutics: Investment Case
12:48PM ET 4/16/2019 Seeking Alpha

Biotech Bonanza: The Mergers And Acquisitions Theme
2:55PM ET 2/13/2019 Seeking Alpha

Company Profile

Business DescriptionEsperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI. View company web site for more details
Address3891 Ranchero Drive
Ann Arbor, Michigan 48108
Number of Employees76
Recent SEC Filing07/01/20194
President, Chief Executive Officer & DirectorTim M. Mayleben
Chief Financial Officer & SecretaryRick Bartram
Executive Vice President-Research & DevelopmentNarendra D. Lalwani
Senior Vice President-Clinical DevelopmentWilliam J. Sasiela

Company Highlights

Price Open$43.51
Previous Close$43.34
52 Week Range$36.06 - 60.99
Market Capitalization$1.1 B
Shares Outstanding26.9 M
SectorHealth Technology
Next Earnings Announcement08/01/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.74
Beta vs. S&P 500N/A
Net Profit Margin-46.97%
Return on Equity-48.63%

Analyst Ratings as of 07/12/2019

Consensus RecommendationConsensus Icon
Powered by Factset